Meeting
2023 ASCO Annual Meeting
A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity.
Authors
Danny Rischin
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Danny Rischin , Stephen John O'Leary , Christopher David Hart , Chandra Sai Diwakarla , Nagashree Seetharamu , John Lee , Shane Raines , Heather M Wolff , Pablo Lapuerta , Benedict J Panizza , Tera Quigley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04262336
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6043)
DOI
10.1200/JCO.2023.41.16_suppl.6043
Abstract #
6043
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high-dose cisplatin chemotherapy to reduce ototoxicity.
First Author: Benedict J. Panizza
Poster
2012 ASCO Annual Meeting
Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study.
First Author: Eric S. Winer
Poster
2023 ASCO Annual Meeting
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.
First Author: Sun Young Rha
Poster
2023 ASCO Annual Meeting
Safety and efficacy of cannabidiol in the management of chemotherapy-induced peripheral neuropathy.
First Author: Marisa C. Weiss